시장보고서

상품코드

2049342

비침습적 산전 검사 시장 보고서 : 제품 유형별, 검사 유형별, 기술별, 방법별, 용도별, 최종사용자별, 지역별(2026-2034년)

Non-Invasive Prenatal Testing Market Report by Product Type, Test Type, Technology, Method, Application, End-User, and Region 2026-2034

발행일: 2026년 05월 | 리서치사: 구분자

IMARC | 페이지 정보: 영문 147 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 3,999

￦ 6,210,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,999

￦ 7,762,000

PDF & Excel (Corporate License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 가능합니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,999

￦ 9,315,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 비침습적 산전 검사(NIPT) 시장 규모는 2025년에 52억 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 13.30%로 성장하여 2034년까지 시장 규모가 164억 달러에 달할 것으로 예측하고 있습니다.

비침습적 산전 검사(NIPT)는 임산부의 혈액 샘플을 이용해 태아의 이상 유무를 검사하는 산전 선별검사의 일종입니다. 이 검사는 주로 산모의 혈액 내 DNA 조각을 분석하여 다운증후군(21번 삼염색체), 에드워즈 증후군(18번 삼염색체), 파토 증후군(13번 삼염색체), 터너 증후군과 같은 유전성 질환을 진단하는 데 사용됩니다. 이 검사를 통해 융모막 검사(CVS)와 같은 위험한 침습적 시술이 필요 없어 임신 9주 이후부터 시행할 수 있습니다.

태아 유전성 질환의 유병률 증가는 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한, 생명과학 및 헬스케어 산업의 기술 발전도 시장 성장을 견인하고 있습니다. 예를 들어, DNA 시퀀싱 기술, 재생의학, 분자 연구의 획기적인 발전은 심각한 질병의 위험을 조기에 예방할 수 있는 엄청난 잠재력을 창출하고 있습니다. 또한, 산전 검사 수검률의 증가와 더불어 일반인들의 건강 의식이 높아지면서 산전 검사의 장점과 중요성에 대한 인식이 확산되고 있는 것도 시장 성장에 힘을 보태고 있습니다. 의료진과 임산부는 척추이분증, 구개열, 겸상적혈구빈혈 등 다른 유전성 질환을 진단하고 태아 발달 초기에 치료할 수 있는 대체 수단을 채택하고 있습니다. 또한, 고령 출산(35세 이상) 추세의 변화도 시장 성장에 긍정적인 영향을 미치고 있습니다. 출산 연령의 증가는 고혈압, 생식능력 저하, 유산 위험, 태아의 염색체 이상 위험 증가 등 여러 가지 건강상의 합병증을 유발할 수 있습니다.

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother's blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus.

KEY MARKET SEGMENTATION :

Breakup by Product Type:

Consumables
Instruments

Breakup by Test Type:

Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others

Breakup by Technology:

NGS
WGS
Others

Breakup by Method:

Ultrasound Detection
Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others

Breakup by Application:

Trisomy
Microdeletion Syndrome
Others

Breakup by End-User:

Hospitals
Diagnostic Laboratories
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

COMPETITIVE LANDSCAPE:

The report provides a comprehensive analysis of the competitive landscape in the global non-invasive prenatal testing market with detailed profiles of all major companies, including:

Berry Genomics
BGI
CENTOGENE GmbH
Eurofins LifeCodexx GmbH
F. Hoffmann-La Roche Ltd
Igenomix
Illumina, Inc.
Laboratory Corporation of America Holdings
MedGenome
Myriad Genetics, Inc.
Natera, Inc.
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Yourgene Health

Key Questions Answered in This Report

1. What was the size of the global non-invasive prenatal testing market in 2025?

2. What is the expected growth rate of the global non-invasive prenatal testing market during 2026-2034?

3. What are the key factors driving the global non-invasive prenatal testing market?

4. What has been the impact of COVID-19 on the global non-invasive prenatal testing market?

5. What is the breakup of the global non-invasive prenatal testing market based on the product type?

6. What is the breakup of the global non-invasive prenatal testing market based on the test type?

7. What is the breakup of the global non-invasive prenatal testing market based on the technology?

8. What is the breakup of the global non-invasive prenatal testing market based on the method?

9. What is the breakup of the global non-invasive prenatal testing market based on the application?

10. What is the breakup of the global non-invasive prenatal testing market based on the end-user?

11. What are the key regions in the global non-invasive prenatal testing market?

12. Who are the key companies/players in the global non-invasive prenatal testing market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Non-Invasive Prenatal Testing Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product Type

6.1 Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Test Type

7.1 Materni 21
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Harmony
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Panaroma
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Verifi
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 NIFTY
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Technology

8.1 NGS
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 WGS
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Method

9.1 Ultrasound Detection
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Biochemical Screening Tests
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Cell-Free DNA in Maternal Plasma Tests
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Fetal Cells in Maternal Blood Tests
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Application

10.1 Trisomy
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Microdeletion Syndrome
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Others
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by End-User

11.1 Hospitals
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
11.2 Diagnostic Laboratories
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
11.3 Others
- 11.3.1 Market Trends
- 11.3.2 Market Forecast

12 Market Breakup by Region

12.1 North America
- 12.1.1 United States
  - 12.1.1.1 Market Trends
  - 12.1.1.2 Market Forecast
- 12.1.2 Canada
  - 12.1.2.1 Market Trends
  - 12.1.2.2 Market Forecast
12.2 Asia Pacific
- 12.2.1 China
  - 12.2.1.1 Market Trends
  - 12.2.1.2 Market Forecast
- 12.2.2 Japan
  - 12.2.2.1 Market Trends
  - 12.2.2.2 Market Forecast
- 12.2.3 India
  - 12.2.3.1 Market Trends
  - 12.2.3.2 Market Forecast
- 12.2.4 South Korea
  - 12.2.4.1 Market Trends
  - 12.2.4.2 Market Forecast
- 12.2.5 Australia
  - 12.2.5.1 Market Trends
  - 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
  - 12.2.6.1 Market Trends
  - 12.2.6.2 Market Forecast
- 12.2.7 Others
  - 12.2.7.1 Market Trends
  - 12.2.7.2 Market Forecast
12.3 Europe
- 12.3.1 Germany
  - 12.3.1.1 Market Trends
  - 12.3.1.2 Market Forecast
- 12.3.2 France
  - 12.3.2.1 Market Trends
  - 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
  - 12.3.3.1 Market Trends
  - 12.3.3.2 Market Forecast
- 12.3.4 Italy
  - 12.3.4.1 Market Trends
  - 12.3.4.2 Market Forecast
- 12.3.5 Spain
  - 12.3.5.1 Market Trends
  - 12.3.5.2 Market Forecast
- 12.3.6 Russia
  - 12.3.6.1 Market Trends
  - 12.3.6.2 Market Forecast
- 12.3.7 Others
  - 12.3.7.1 Market Trends
  - 12.3.7.2 Market Forecast
12.4 Latin America
- 12.4.1 Brazil
  - 12.4.1.1 Market Trends
  - 12.4.1.2 Market Forecast
- 12.4.2 Mexico
  - 12.4.2.1 Market Trends
  - 12.4.2.2 Market Forecast
- 12.4.3 Others
  - 12.4.3.1 Market Trends
  - 12.4.3.2 Market Forecast
12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast

13 SWOT Analysis

13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Berry Genomics
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
- 16.3.2 BGI
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
- 16.3.3 CENTOGENE GmbH
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Eurofins LifeCodexx GmbH
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
- 16.3.5 F. Hoffmann-La Roche Ltd
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 SWOT Analysis
- 16.3.6 Igenomix
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
  - 16.3.6.3 Financials
- 16.3.7 Illumina, Inc.
  - 16.3.7.1 Company. Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Laboratory Corporation of America Holdings
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 MedGenome
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Myriad Genetics, Inc.
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Natera, Inc.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
- 16.3.12 Quest Diagnostics Incorporated
  - 16.3.12.1 Company Overview
  - 16.3.12.2 Product Portfolio
  - 16.3.12.3 Financials
  - 16.3.12.4 SWOT Analysis
- 16.3.13 Thermo Fisher Scientific Inc.
  - 16.3.13.1 Company Overview
  - 16.3.13.2 Product Portfolio
  - 16.3.13.3 Financials
  - 16.3.13.4 SWOT Analysis
- 16.3.14 Yourgene Health
  - 16.3.14.1 Company Overview
  - 16.3.14.2 Product Portfolio
  - 16.3.14.3 Financials

비침습적 산전 검사 시장 보고서 : 제품 유형별, 검사 유형별, 기술별, 방법별, 용도별, 최종사용자별, 지역별(2026-2034년)

Non-Invasive Prenatal Testing Market Report by Product Type, Test Type, Technology, Method, Application, End-User, and Region 2026-2034

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 비침습적 산전 검사 시장

제6장 시장 내역 : 제품 유형별

제7장 시장 내역 : 테스트 유형별

제8장 시장 내역 : 기술별

제9장 시장 내역 : 방법별

제10장 시장 내역 : 용도별

제11장 시장 내역 : 최종사용자별

제12장 시장 내역 : 지역별

제13장 SWOT 분석

제14장 밸류체인 분석

제15장 Porter's Five Forces 분석

제16장 경쟁 구도